Previous Article | Next Article ![]()
Journal of Virology, October 2006, p. 10162-10172, Vol. 80, No. 20
0022-538X/06/$08.00+0 doi:10.1128/JVI.00249-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Centre for Immunology, St. Vincent's Hospital, Sydney, NSW, Australia,1 National Centre in HIV Epidemiology and Clinical Research, University of NSW, Sydney, NSW, Australia,2 Partners AIDS Research Center, Massachusetts General Hospital, Boston, Massachusetts,3 Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia,4 Rush University, Chicago, Illinois,5 Taylor Square Private Clinic, Sydney, NSW, Australia6
Received 3 February 2006/ Accepted 6 July 2006
|
|
|---|
|
|
|---|
Therefore, we hypothesized that activated, proliferating HIV-specific CD4+ T cells coexpressing CCR5 and high levels of CD38 would be prime targets for HIV-1 infection in vivo during PHI. In our previous cross-sectional study, these cells appeared only transiently, exhibiting a rapid decline approximately 2 to 3 weeks following the onset of symptoms of the acute viral illness (94), consistent with cytopathic infection in vivo.
Dramatic losses of
CCR5+ CD4+ T cells as a result of
cytopathic infection, particularly in the gut, have been reported in
primary simian immunodeficiency virus (SIV) infection
(40,
45,
82), and a similar loss
of gut CD4+ T cells occurs in primary HIV infection
(7,
22,
48). If cytopathic
infection of CCR5+ CD4+ T cells
is particularly localized to gut-associated lymphoid tissue (GALT),
then the trafficking of CCR5+ HIV-specific
CD4+ T cells to GALT might also contribute to the
rapid loss of these cells. The homing of memory CD4+
T cells to GALT is determined by the coexpression of the
integrins
4 (CD49d) and ß7, which specify binding to
the mucosal vascular addressin MAdCAM-1
(42,
59,
87). A previous study of
PHI reported a selective loss of
CCR5+
4ß7+
CD62L-negativeCD45RO+ CD4+ T
cells from the circulation
(34), suggesting that the
expression of gut-homing integrins
4 (CD49d) and ß7 on
CCR5+ HIV-specific CD4+ T cells
may determine their fates.
However, their transient appearance
could be also be due to normal homeostatic processes, such as apoptosis
or feedback regulation, since a similar peak of CD4+
T-cell responses has also been observed in other acute viral infections
in both mice (80) and
humans (3,
18,
55). HIV-specific
CD4+ T cells during PHI were found to contain low
levels of Bcl-2 (94),
which has previously been associated with a propensity to undergo
apoptosis in vitro and in vivo
(74). Precursors of
long-term memory CD4+ and CD8+ T
cells in murine models selectively express IL-7R
(CD127),
which may play a role in sparing these cells from apoptosis by
mediating the signaling leading to the reexpression of Bcl-2
(20,
30,
39,
63). However, 80 to 90%
of HIV-specific CD4+ T cells lack CD127 during PHI
(94), consistent with a
predetermined apoptotic fate for most
CCR5+CD38+++
CD4+ T cells.
Apart from apoptosis, the down-regulation of a CD4 T-cell response is also believed to be mediated by feedback inhibition exerted by CD25+ CD4+ T regulatory (T reg) cells, which have been shown to be important in the control of CD4-mediated inflammatory diseases (60). CD25+ T reg cells may also express CTLA-4, an important negative signaling molecule (56, 61, 76). The suppressive influence of CTLA-4 signaling has been inferred from the early fatal CD4+ lymphoproliferation observed in CTLA-4 gene knockout mice (78, 85). We previously observed that, compared to the expression of CTLA-4 by T cells from HIV-negative controls, intracellular CTLA-4 expression was greatly increased during PHI, especially in CD8+ T cells, when maximally stimulated with phorbol myristate acetate and ionomycin (J. Zaunders et al., unpublished results).
Therefore, in the
current study we aimed to determine the extent to which all of these
various factors may exert a negative influence on
CCR5+CD38+++
HIV-specific CD4+ T cells during PHI. We measured
their rate of infection with HIV-1 DNA, their rate of spontaneous
apoptosis, as well as their expression of the gut-homing integrins
4 and ß7, and also the possible generation of
CTLA-4+ T regulatory cells during PHI. The results
suggest that none of these factors alone leads to the loss of
HIV-specific CD4+ T cells during the resolution of
PHI but instead point to a complex multifactorial process that results
in an impaired response.
|
|
|---|
Six HIV+ subjects with established infections but undetectable plasma HIV RNA viral loads (<50 copies/ml) and without antiretroviral therapy at the time of study were also included and are referred to as "HIV+ controllers."
Healthy HIV-negative university and hospital staff members were recruited as controls for this study. The PHAEDRA/CORE 01 study was approved by the St. Vincent's Hospital Ethics Committee, and all subjects gave written informed consent.
T-lymphocyte phenotyping of fresh whole blood.
The
monoclonal antibodies used were CD3-PerCP-Cy5.5 and -Pacific Blue;
CD4-phycoerythrin (PE)-Cy7, -Alexa Fluor 700, and -allophycocyanin
(APC); CD8-Alexa Fluor 700 and -APC-Cy7; CD38-PE-Cy7, -APC, and -PE;
CCR5-fluorescein isothiocyanate (FITC) gamma interferon
(IFN-
)-APC; CD45RO-FITC; CD25-APC; CD49d-PE; integrin
ß7-APC; activated caspase-3-PE; CTLA-4-PE; CD19-PE-Cy7;
CD56-APC; CD16-APC-Cy7; HLA-DR-FITC; and CD123-PE (Becton Dickinson,
San Jose, CA); CD4-energy-coupled dye (ECD), CD45RO-ECD, and IL-7R
(CD127)-PE (Beckman Coulter, Hialeah, FL); and CD62L-APC-Cy7
(eBioscience, San Diego, CA). All antibodies were used
according to the manufacturers' directions.
The staining of CD4+ T-cell subsets in fresh peripheral blood was performed as previously described (91, 94) on whole blood within 1 h of venepuncture to minimize spontaneous loss of CCR5 expression. T regulatory CD4+ T-cell subsets were analyzed by five-color flow cytometry on an LSR II flow cytometer (Becton Dickinson) using CD3-PerCP-Cy5.5, CD4-PE-Cy7, CD25-APC, CD127-PE, and CD45RO-FITC as described elsewhere (65a). Foxp3 expression was studied in CD3-PerCP-Cy5.5+CD4-PE-Cy7+CD25-FITC+CD127-PElow cells using Foxp3-APC (eBioscience) according to the manufacturer's directions.
The immunophenotyping of gut-homing CD4+ T cells was analyzed by nine-color flow cytometry on the three-laser LSR II by staining with CD3-Pacific Blue, CD4-Alexa Fluor 700, CD8-APC-Cy7, CD45RO-ECD, CD38-PE-Cy7, HLA-DR-PerCP, CCR5-FITC, integrin ß7-APC, and CD49d-PE. For analysis, a minimum of 100,000 events were collected. Spectral compensations were set using cells stained individually with the different fluorochrome conjugates and validated by staining peripheral blood mononuclear cells (PBMCs) with combinations of CD3-Pacific Blue, CD4-ECD, CD8-Alexa Fluor 700, CD19-PE-Cy7, CD56-APC, CD16-APC-Cy7, HLA-DR-PerCP, CD123-PE, and CD14-FITC monoclonal antibodies and obtaining expected patterns (data not shown).
Purification of CD4+ T-cell subsets by cell sorting of PBMCs. Cryopreserved PBMCs from three PHAEDRA/CORE 01 subjects and a further three subjects, who had been included in a previous study (68), at presentation of PHI were used in cell sorting experiments. These PBMCs were obtained a median of 8 days after the onset of symptoms. Cryopreserved PBMCs (12 x 106 to 17 x 106) obtained from three subjects were thawed and stained with CD4-APC and CD38-PE. Cells were washed once with phosphate-buffered saline, fixed with 3% paraformaldehyde in phosphate-buffered saline for 30 min on ice, and then sorted using a FACSVantage by running FACSDiva software (version 4.1; Becton Dickinson). Four populations were obtained from PBMCs: CD38+++CD4+ and CD38dimCD4+ (Fig. 1A) as well as CD4-ve lymphocytes and monocytes defined as CD4dim and high side scatter cells. The purity of the cell subpopulations was >98% in all cases.
![]() View larger version (34K): [in a new window] |
FIG. 1. HIV
DNA in CD38+++ and
CD127+ subpopulations of CD4+
cells from PBMCs during PHI. A representative dot plot of
CCR5+CD38+++
CD4+ T cells present in fresh whole blood during PHI
is shown in panel A, and a representative comparison of CD38 expression
on CD4+ T cells between a subject during PHI and a
healthy adult control subject is shown in panel B. PBMCs were stained
with CD4-APC and CD38-PE (C) or CD4-APC and CD127-PE
(D) and sorted into different subpopulations. Representative
histograms for each of the two sorting protocols are shown. DNA was
extracted from purified cells, and the number of copies of HIV DNA per
cell in each subpopulation was determined by quantitative PCR and
normalized to beta-actin. Each column shows the mean (and standard
error) from three independent experiments for each subpopulation of
CD4+ cells defined by CD38 (E) or CD127
(F) as well as for the corresponding unsorted PBMC
samples.
|
HIV-1 DNA quantification. HIV-1 DNA was quantified by a real-time PCR assay specific for HIV-gag using the Rotor-Gene 3000 (Corbett Research, Sydney, Australia). HIV-1 DNA was compared with genomic DNA, determined by beta-actin detection as previously described (75). Both real-time assays used sequence-specific fluorogenic TaqMan probes. Standard curves were constructed by using pNL4-3 and purified human DNA (Sigma). The primers and probes used were the HIV-gag sense primer 5'-AGTGGGGGGACATCAAGCAGCCATGCAAAT-3', antisense primer 5'-TACTAGTAGTTCCTGCTATGTCACTTCC-3', detection probe 5'-6-carboxyfluorescein-ATCAATGAGGAAGCTGCAGAATGGGATAG-6-carboxytetramethylrhodamine-3', beta-actin sense primer 5'-TCACCCACACTGTGCCCATCTACGA-3', beta-actin antisense primer 5'-CAGCGGAACCGCTCATTGCCAATGG-3', and detection probe 5'-6-carboxyfluorescein-ATGCCCTCCCCCATGCCATCCTGCG-6-carboxytetramethylrhodamine-3'. DNA extraction from sorted cells was performed using the High Pure viral nucleic acid reagents (Roche, Castle Hill, Australia) with an extended 16-h protease K digestion incubation at 56°C. To estimate the number of copies of HIV DNA per cell, it was assumed that the yield of DNA extracted was 1 ng per 150 cells (12).
Intracellular cytokine assay.
HIV
Gag-specific CD4+ T cells were identified by using a
6-h whole-blood intracellular cytokine assay with six-color flow
cytometry, as previously described
(91,
94). Overlapping HIV-1
Gag 15-mer peptides, obtained from the NIH AIDS reference reagents
program (catalog no. 11057), were used as a pool of 122
peptides at an individual concentration of 2 µg/ml
each. Cytomegalovirus (CMV)-specific CD4+ T cells
were identified as previously described
(91,
94). For analysis,
300,000 events were collected. T lymphocytes were first gated on
CD3-PerCP-Cy5.5 versus side scatter and then on
CD4-PE-Cy7-positive/CD8-APC-Cy7-negative cells. Finally,
IFN-
-APC+ cells were analyzed for
staining with either CTLA-4-PE or activated
caspase-3-PE.
Statistical analyses. All statistical tests were performed using StatView 5.0 for Macintosh (Abacus Concepts, Berkeley, CA). Results for replicate experiments are shown as means and standard errors. Results for each subject group are shown as medians and interquartile ranges. The Mann-Whitney U test was performed to compare continuous variables between subject groups. A two-sided P value of <0.05 was considered statistically significant.
|
|
|---|
DNA was extracted
from the different subpopulations, and real-time PCR was used to
measure copy numbers of HIV-1 DNA normalized to beta-actin (Fig.
1E). Very few copies
(
1 per 1,000 cells) of HIV-1 DNA were detected in CD4-negative
lymphocyte or monocyte subpopulations (data not shown). However, both
CD38+++ CD4+ T
cells and CD38dim CD4+ T cells contained comparable
levels of HIV-1 DNA on a per cell basis, and both purified
subpopulations were enriched for HIV-1 DNA relative to the starting
PBMCs (Fig. 1E).
The number of HIV-1 DNA copies per cell indicate that if all infected cells contained only one copy of HIV-1 DNA each, then 10 to 15% of CD4+ T cells were infected. In a recent study of acute SIV infection, it was shown by single-cell analysis that infected cells contained an average of 1.5 copies per infected cell (45), consistent with previous studies of chronic HIV-1 infection (19, 29). Therefore, there is probably an upper limit of about 10% infected cells in both the activated CD38+++ and nonactivated CD38dim CD4+ T-cell subpopulations.
The results show that there was no preferential infection of the activated CD38+++ CD4+ T cells, despite our previous observation that they were predominantly CCR5+ in fresh whole blood. Instead, since a large majority of CD4+ T cells were CD38dim (Fig. 1A), then the majority of the copies of HIV-1 DNA in PBMCs were in the nonactivated CD38dim subpopulation.
Similarly, low CD127 expression was also used to enrich HIV-specific CD4+ T cells (94) in order to measure infection with HIV-1 DNA. Unexpectedly, purified CD127+ CD4+ T cells (Fig. 1D) were found to contain a disproportionately higher number of copies of HIV-1 DNA, fivefold more on a per cell basis than the more-activated CD127-negative CD4+ T cells (Fig. 1F). Similar to the CD38dim CD4+ T cells, the CD127+ subset makes up the greater part of CD4+ T cells within PBMCs, and therefore the vast majority of copies of HIV-1 DNA were in the CD127+ subset of CD4+ T cells. Conversely, during PHI, 80 to 90% of HIV-specific CD4+ T cells are CD127 negative (94), again suggesting that the majority of HIV-specific CD4+ T cells are not directly infected in vivo.
Combining the results of the two sets of sorting experiments suggests that the CD38+++ CD4+ T cells that are infected will be the 10 to 20% that are also CD127+ (94). However, in the current studies, there were insufficient cells available to directly confirm that CD38+++CD127+ CD4+ cells were highly infected; this will be addressed in future studies.
Apoptosis of HIV-specific CD4+ T cells.
Since we estimated that only a minority
of CCR5+CD38+++
CD4+ T cells were infected with HIV-1 DNA, the loss
of these cells from the circulation
(94) may not be due to
direct cytopathic effect. We previously found that the rate of
spontaneous apoptosis, in vitro, of CD4+ T cells
from subjects with PHI was slightly elevated compared to that from
healthy adult controls
(93), and we expected to
observe preferential apoptosis of IFN-
+
gag-specific CD4+ T cells in early PHI, as
was previously described for antigen-specific CD4+ T
cells in chronic HIV-1 infection
(89). Activated
intracellular caspase-3 was used as a marker of apoptotic
CD4+ T cells, in combination with the intracellular
cytokine assay, by using fresh whole-blood samples from subjects in
four independent experiments (Fig.
2A). The results in all cases showed that IFN-
+
Gag-specific CD4+ T cells were clearly separate from
apoptotic activated caspase-3+
CD4+ T cells. Therefore, we were unable to
demonstrate directly a high rate of spontaneous apoptosis of
Gag-specific CD4+ T cells that actively produced
IFN-
. Similarly, antigen-specific CD8+ T
cells in the same samples were not positive for activated caspase-3,
despite a very high level of apoptosis among CD8+ T
cells (Fig. 2B).
![]() View larger version (37K): [in a new window] |
FIG. 2. Lack
of apoptosis of Gag-specific CD4+ T cells in vitro
during PHI. Following stimulation with Gag peptides in the
intracellular cytokine assay, CD4+ (A) and
CD8+ (B) T cells were simultaneously
stained with monoclonal antibodies to IFN- and activated
caspase-3. Representative histograms for one subject out of four
consecutive subjects with PHI are shown. Also shown are percentages of
cells in
quadrants.
|
Trafficking of CCR5+CD38+++ CD4+ T cells during primary HIV-1 infection. A third possible reason for the rapid loss of CCR5+CD38+++ CD4+ T cells from circulation could be the sequestration in tissues, as shown for CD8 effector cells in mice (44). Since it has recently been reported that gut lymphoid tissue is a major site of HIV-1 during primary infection (7, 22, 48), we examined the coexpression of the gut-homing markers CD49d and integrin ß7 on CD4+ T cells during PHI, in particular on the CD45RO+ memory cell and CCR5+CD38+++ HIV-specific subsets of CD4+ T cells, respectively (Fig. 3A). The proportions of CD45RO+ memory CD4+ T cells expressing CD49d and integrin ß7 were similar between controls and 12 consecutive subjects presenting during PHI (Fig. 3B), suggesting that there was no preferential loss of this circulating subset of memory CD4+ T cells. However, for the subjects with PHI, a median of 41% of CCR5+CD38+++ CD4+ T cells was found to be positive for the gut-homing markers CD49d and integrin ß7, which was generally higher than that for CD45RO+ memory CD4+ T cells (Fig. 3B). These results suggest that a large fraction of the CCR5+CD38+++ CD4+ T cells present during PHI will preferentially traffic to gut-associated lymphoid tissue.
![]() View larger version (20K): [in a new window] |
FIG. 3. Gut-homing
of CCR5+ CD4+ T cells during PHI.
Fresh whole-blood samples were stained for CD3, CD4, CD45RO,
CD62L, integrin
ß7, CD49d (integrin 4), CCR5, and CD38. Gut-homing
CD4+ T cells were identified by coexpression of
integrin ß7 and CD49d. (A) The presence of integrin
ß7+CD49d+ cells within
CD45RO+ and
CCR5+CD38+++
CD4+ T-cell subsets is shown for 1 representative
subject out of 12 subjects studied during PHI. The percentages of
integrin ß7+CD49d+ cells
within their respective CD45RO+ and
CCR5+CD38+++
CD4+ T-cell subsets are shown. (B) Box
plots of integrin
ß7+CD49d+ cells as a
percentage of CD45RO+CD4+ T cell
for the three subject groups (left) and as a percentage of
CCR5+CD38+++
CD4+ T cells for subjects with PHI only (right).
Fresh whole-blood samples were also stained for CD3, CD4, CD45RO,
CD62L, integrin ß7, CCR5, and CD127. The
CCR5+CD127+ subset present in a
representative healthy adult control subject is shown in panel C,
together with its expression of CD45RO, integrin ß7, and CD62L.
Box plots of CCR5+CD127+ cells as
a percentage of CD4+ are shown at the left side of
panel D, and ß7+CD45RO+
and CD45RO+CD62L-negative cells as percentages of
CCR5+CD127+
CD4+ T cells are also shown at the right side of the
panel. Box plots depict the 90th, 75th, median, 25th, and
10th percentiles for each subject group, and the number of subjects in
each group is shown. The P values shown are for subjects with
PHI compared to those for healthy adult controls by a Mann-Whitney
nonparametric
test.
|
CD25+ CD4+ T regulatory cells during primary HIV-1 infection. Another possible reason for the loss of antigen-specific CD4+ T cells during the resolution of PHI may be the development of CD25+ CD4+ T regulatory cells, which were recently reported in chronic HIV-1 infection (1, 33). We determined whether there was an elevation in the proportion or number of circulating CD25+ CD4+ T regulatory cells in subjects with PHI, compared to that in healthy adult controls. T regulatory cells were identified by an improved phenotypic method, combining increased expression of CD25 with reduced CD127 expression (Fig. 4A) (65a), and validated by the confirmation of the expression of Foxp3 selectively within these cells (Fig. 4B).
![]() View larger version (26K): [in a new window] |
FIG. 4. T
regulatory cells during PHI. T reg
CD3+CD4+ cells were identified
within CD45RO+ and CD45RO
populations by high expression of CD25 and dim expression of CD127 (A).
Representative histograms for a subject during PHI are shown. Identical
gating was used for all cohorts. The selective expression of
Foxp3 within CD25+CD127low CD4+ T
cells, compared with that for the remaining CD4+ T
cells, is shown in panel B. Overall results for all cohorts with the
numbers of subjects in each cohort are shown in panel C. The results
for each subpopulation are expressed as percentages of total
CD4+ T cells. Box plots depict 10th, 25th, median,
75th, and 90th percentiles. The P value shown is for subjects
with PHI compared to that for healthy adult controls, by a Mann-Whitney
nonparametric
test.
|
However, commensurate with the decrease in total CD4 T-cell counts in subjects with PHI, there was a decrease in the absolute numbers of T reg cells in subjects with PHI, compared to that in healthy adult controls (data not shown).
CTLA-4 expression by HIV-specific CD4+ T cells.
CTLA-4 may be involved in T reg
activity (61), and we
previously observed that there was increased expression of CTLA-4 by
polyclonally stimulated T cells during PHI (J. Zaunders et al.,
unpublished). Therefore, we used the intracellular cytokine assay to
assess intracellular expression of CTLA-4 by HIV-specific
CD4+ T cells in response to antigen stimulation in
vitro. The results show that a very large proportion of
IFN-
+ Gag-specific CD4+
T cells coexpressed CTLA-4 during PHI (Fig.
5A).
![]() View larger version (38K): [in a new window] |
FIG. 5. CTLA-4
expression by gag-specific CD4+ T cells
during PHI. (A) Following the stimulation of whole blood from
a healthy adult control with CMV lysate or from a subject during PHI
with either CMV lysate or Gag peptides, in the intracellular cytokine
assay, CD4+ T cells were simultaneously stained with
monoclonal antibodies to IFN- and CTLA-4. Representative
histograms are shown. (B) Overall results for all cohorts are
shown with the number of subjects in each cohort. The results for
CTLA-4+ cells are expressed as percentages of
IFN- + CD4+ T cells. Box
plots depict the 10th, 25th, median, 75th, and 90th
percentiles.
|
Importantly, Gag-specific CD4+ T cells from HIV+ controllers also expressed a very low level of CTLA-4 in response to antigen-specific restimulation in vitro in contrast to the high level of CTLA-4 expression by HIV-1 Gag-specific CD4+ T cells in subjects with PHI (Fig. 5B).
|
|
|---|
While the initial results showed the presence of HIV-1 DNA in highly activated CD38+++ CD4+ T cells within the first weeks of symptomatic primary HIV-1 infection, the extent of infection of the CD38+++ CD4+ T cells in vivo appeared to be restricted. It was likely that only approximately 10% of these cells were infected, based on an average infection rate of 1.5 copies per infected cell (45). Therefore, the rapid decline in CCR5+CD38+++ HIV-specific CD4+ T cells in the circulation that we previously observed (94) was probably only partly due to cytopathic infection. This conclusion is supported by a parallel study of vaccinia virus-specific CD4+ T cells, where we observed a similar peak of antigen-specific CCR5+ CD38+++ CD4+ T cells, followed by a decline coincident with the resolution of the vaccinia virus infection (95).
Nevertheless, cytopathic infection probably remains a significant factor in the decline of CCR5+ HIV-specific CD4+ T cells. Previously, we found that proliferating CCR5+ Ki-67+ CD4+ T cells did not accumulate in the circulation during PHI, in contrast to a marked accumulation of CCR5+ Ki-67+ CD4+ T cells in subjects with acute Epstein-Barr virus infection (92). A dramatic loss of CCR5+ CD4+ T cells, particularly in the gut, has been reported in acute SIV infection (40, 45, 82) and a similar loss of gut CD4+ T cells may occur in primary HIV infection (7, 22, 48). It is therefore notable that during PHI, just under half of the circulating CCR5+CD38+++ CD4+ T cells expressed the gut-homing markers CD49d and integrin ß7.
Since the vast majority of HIV-1 DNA was found in CD127+ CD4+ T cells, we investigated the expression of CCR5 on these cells both in healthy adults and during PHI. Around 10% of CD4+ T cells in peripheral blood are CCR5+CD127+, but in healthy adults, nearly half also express integrin ß7, suggesting trafficking to GALT. It is possible that the CCR5+CD127+ß7+ CD4+ T cells subset is a significant target for HIV-1 infection due to direct infection of resting cells in GALT, as seen in the acute SIV infection model (40). In our current study, the overall proportion of gut-homing CD45RO+ memory cells in the circulation was not apparently reduced but theCCR5+CD127+ß7+CD62L-negative subset of CD4+ T cells appeared to be selectively depleted during PHI.
Our findings are consistent with those of an
earlier report of reduced circulating
4ß7+ CCR5+
CD4+ T cells during PHI
(34) as well as those of
a previous study of acute SIV infection which reported a loss of the
small subset of CD4+ T cells expressing CD103
(integrins
Eß7)
(46), although this may
direct localization around E-cadherin+ epithelial
cells within GALT rather than direct trafficking to GALT
(32). Detailed studies of
cells from biopsies of GALT are therefore required to clarify the fate
of HIV-specific CD4+ T cells.
The level of HIV-1 DNA within CD127+ CD4+ T cells was much higher than that in their CD127-negative counterparts. We had previously shown that the CD127-negative subpopulation of T cells contained most of the HIV-specific CD4+ T cells (94) but also contained highly activated CD38+, Ki-67+, and Bcl-2low cells prone to apoptosis during PHI (93). The observation that CD127+ CD4+ T cells are highly infected has two important implications for HIV-1 pathogenesis.
First, murine studies suggest that the small CD127+ subset of CCR5+CD38+++ HIV-specific effector CD4+ T cells that we previously observed (94) represents precursors of long-term memory CD4+ T cells (30, 39, 63). Therefore, HIV-1 infection may preferentially target these nascent HIV-specific memory CD4+ T cells. Future large-scale cell sorting experiments are required to purify sufficient CD127+CCR5+CD38+++ effector CD4+ T cells as well as CD127+ß7+ CD4+ T cells to confirm that these cells are highly infected as implied by our current results.
Second, there is an essential role for frequent signaling by IL-7 in memory T-cell survival (38, 63, 66, 77). However, several studies have shown that the culture of PBMCs from subjects with chronic HIV-1 infection in the presence of IL-7 efficiently leads to the production of HIV-1 (9, 49, 69), specifically from latently infected resting cells (83), probably involving the induction of NF-kB (8, 17).
Other studies
have shown that treatment of PBMCs with IL-7 makes resting
CD4+ T cells permissive for productive HIV-1
infection (17,
64,
71,
81) without necessarily
entering the cell cycle
(81). Signaling by the
IL-7 receptor leads to the up-regulation of NF-kB (reviewed in
reference 28), which is a
major transcription factor for the initiation of HIV-1 replication
(reviewed in reference
57). We have found that
plasma levels of IL-7 were elevated during PHI, and normal expression
of the
chain of the IL-7 receptor was perturbed
(62). Taking these
results together, it is therefore possible that increased IL-7
signaling in vivo can contribute significantly to promoting the
infection of otherwise apparently resting CCR5+
CD127+ CD4+ T cells during PHI.
High levels of infection of resting CD4+ T cells
have been reported in lymphoid tissue during acute SIV infection
(97), particularly in
GALT (40),
where IL-7 production is well described
(28,
84). Subsequently, the
homeostasis of resting CD4+ T cells, involving
intermittent delivery of the IL-7 survival signal
(38,
63,
66,
77), may lead to the
depletion of CD127+ CD4+ T cells
containing HIV-1 DNA.
Further studies are required to determine whether the HIV-1 DNA in resting CD4+ T cells was fully integrated or remained in a relatively labile unintegrated form (54) and to what extent infectious virus can be recovered from either activated or resting subsets, particularly when incubated with exogenous IL-7.
However, the major mechanism believed to mediate the decrease in effector T cells during the resolution of a primary immune response is apoptosis (43). Central to the apoptosis of CD8+ effector T cells is the balance between antiapoptotic Bcl-2 and proapoptotic Bim (52), while the reexpression of Bcl-2 mediated by IL-7R signaling is reportedly involved in the transition from effector to long-term memory cells (21, 63). We had directly observed a decrease in Bcl-2 expression in HIV-specific CD4+ T cells during PHI (94), so we expected to observe spontaneous apoptosis of these cells in vitro, as has been reported with chronic HIV-1 infection (89). However, this was not observed in our intracellular cytokine assays, even though elevated levels of apoptotic CD4+ and CD8+ T cells were clearly seen, consistent with our previous results (93).
This discrepancy may be due to a difference between chronic and acute HIV-1 infection. Cells committed to apoptosis in acute infection may be unable to produce cytokines in vitro. HLA class II tetramers (65, 67) would provide a more direct means to detect apoptotic antigen-specific CD4+ T cells.
Another possible mechanism of the down-regulation of the HIV-specific response is the suppression by CD25+ CD4+ T regulatory cells (60). While it has recently been reported that T reg cells can be infected by HIV-1 (50), most reports suggest that T reg cells (1, 4, 33, 86) are increased in chronic HIV-1 infection. We observed a slight increase in T reg cells, identified phenotypically in samples from subjects with PHI. It is possible that an effect of cytopathic infection simultaneously limited a potentially greater expansion of T reg cells, but our cell sorting experiments showed few copies of HIV-1 DNA in CD127-negative cells, which include T reg cells, suggesting that they were not preferentially infected.
A major finding is the high level of expression of CTLA-4 by HIV-specific CD4 T cells during PHI, and it is probable that this is a significant factor in their decline. Our results are consistent with reports of increased expression of CTLA-4 in CD4+ T cells in peripheral blood and lymphoid tissue in HIV-1 infection (4, 73), including CCR5+ and Ki-67+ CD4+ T cells (37). Importantly, murine genetic studies have shown that CTLA-4 expression is a potent constraint on CD4+ T-cell expansion in vivo (78, 85). However, it is not clear whether the expression of CTLA-4 by antigen-specific CD4+ T cells themselves is suppressive (16, 26) or whether there is an indirect suppressive effect mediated by other cells, such as T regulatory CD4+ T cells expressing CTLA-4 (5, 61, 79), and we had expected to find an increased expression of CTLA-4 associated with an increase in T reg cells.
The rapid expression of CTLA-4 in response to HIV-1 Gag antigen would be predicted to interfere with CD28 signaling (11, 36), reducing the synthesis and stability of IL-2 mRNA (2). Therefore, the overexpression of CTLA-4 may provide a mechanistic explanation for the lack of IL-2 production and in vitro proliferation by HIV-specific CD4+ effector T cells, which we and others have previously observed in PHI (24, 94) and which is a hallmark of untreated chronic HIV-1 infection (23, 27, 88). An exception may be those rare patients controlling viral replication without therapy who exhibit HIV-specific IL-2 production by CD4+ T cells and proliferation (6, 25, 58, 91). Therefore, it is significant that in the HIV-specific CD4+ T cells from HIV+ controllers included in this study, there was little CTLA-4 production in response to antigenic stimulation. Therefore, one avenue of investigation may be the possible beneficial effect of selectively interfering with the binding of CTLA-4 to B7 molecules on antigen-presenting cells (53).
In our
parallel study of vaccinia virus-specific CD4+ T
effector cells, less than half coexpressed CTLA-4 with IFN-
(95), suggesting an
important difference in cell fate decisions between early HIV- and
vaccinia virus-specific CD4+ T cells. The cause of
the altered differentiation of HIV-specific CD4+ T
cells is currently unknown but could be due to differences in dendritic
cells (35) between the
two infections. HIV-1 infection reportedly leads to decreases in
dendritic cell subsets in the circulation
(13,
51) and alterations of
the phenotype of these cells in lymphoid tissue
(41). Therefore, there
may be alterations in signaling by antigen-presenting cells in the very
early stages of CD4+ memory T-cell differentiation
following HIV-1 infection compared with that following vaccinia virus
inoculation.
Altogether, the overall results of the current study argue against cytopathic infection and apoptosis of activated CCR5+ CD4+ effector T cells or an overabundance of T regulatory cells as major reasons for the loss of HIV-specific CD4+ T cells during the resolution of PHI. Instead our results indicate that the infection of CCR5+ CD127+ CD4+ T cells, including early HIV-specific memory CD4+ T cells that traffic through GALT, may be an important step in pathogenesis. Furthermore, the high level of CTLA-4 expression associated with limited IL-2 production probably plays a role in blocking the proliferative potential and differentiation of HIV-specific CD4+ T cells which escape infection.
The National Centre in HIV Epidemiology and Clinical Research is supported by the Commonwealth Department of Health and Ageing through the Australian National Council on AIDS, Hepatitis C, and Related Diseases. This project was funded by an AIEDRP grant through the NIH Division of AIDS and a program grant from the Australian National Health and Medical Research Council.
The authors have no conflicting financial interests.
Members
of the PHAEDRA Study Team are P. Grey, J. Kaldor, D. A.
Cooper, T. Ramacciotti, K. Petoumenos, D. Smith, M. Bloch, N. Medland,
R. Finlayson, A. McFarlane, N. J. Roth, C. Workman, A. Carr,
A. D. Kelleher, J. Zaunders, and P. Cunningham. ![]()
|
|
|---|
B activation through
interaction with thymic epithelial cells. J.
Virol.
73:2064-2073.
-producing CD4+ T cells in
protection against CMV disease. Blood
101:2686-2692.
4ß7 by circulating CD4+ cells with
memory for intestinal rotavirus. J. Clin.
Investig.
100:1204-1208.[Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»